GlassScriptPhysician profile
Jonathan William Rozack
NPI 1255429288
$2,689.63
in general payments reported to CMS, 2019-2025
35 companies · $1,076 in 2025
The $1,076 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $202 · 2022: $371 · 2023: $404 · 2024: $636 · 2025: $1,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,115.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $709.50 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $255.28 | 2024-2025 | Fanapt |
| Novo Nordisk INC | $198.04 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $181.84 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $131.52 | 2022-2025 | Farxiga, Airsupra |
| Phathom Pharmaceuticals, INC. | $94.75 | 2024-2025 | Voquezna |
| Axsome Therapeutics, INC. | $92.99 | 2024-2025 | Auvelity |
| Pfizer INC. | $87.62 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $85.25 | 2023-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Amgen INC. | $84.25 | 2021-2025 | Repatha, Otezla, Repatha |
| Viatris Specialty LLC | $82.43 | 2025 | Yupelri |
| Insulet Corporation | $72.87 | 2025 | Omnipod |
| Boston Scientific Corporation | $66.49 | 2022-2025 | General - Pain Management, Watchman Flx |
| Corcept Therapeutics | $58.49 | 2025 | Korlym |
| Glaxosmithkline, LLC. | $50.32 | 2022-2023 | Trelegy Ellipta, Bexsero, Arexvy |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Rozack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.